Trevi Therapeutics
TRVI
23 hedge funds and large institutions have $32.9M invested in Trevi Therapeutics in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
220% more capital invested
Capital invested by funds: $10.3M → $32.9M (+$22.6M)
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
35% more funds holding
Funds holding: 17 → 23 (+6)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
23.23% less ownership
Funds ownership: 50.95% → 27.72% (-23%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$1.6M |
| 2 |
WA
WealthTrust Axiom
Wayne,
Pennsylvania
|
+$72.5K |
| 3 |
State Street
Boston,
Massachusetts
|
+$38.2K |
| 4 |
UBV
United Bank (Virginia)
Vienna,
Virginia
|
+$27.7K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$24.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$6.15M |
| 2 |
AC
Armistice Capital
New York
|
-$1.18M |
| 3 |
Renaissance Technologies
New York
|
-$229K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$39K |
| 5 |
Millennium Management
New York
|
-$37.9K |
TRVI Hedge Fund Activity: Q1 2022 in Review
23 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q1 2022, worth a combined $32.9M — up 220% from $10.3M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new TRVI positions and 3 closed out — a net gain of 6 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was MAI Capital Management, opening a new position worth an estimated $1.6M. The largest seller was NEA Management Company, cutting an estimated $6.15M.
- 23 institutional investors held Trevi Therapeutics (TRVI) as of Q1 2022, up from 17 in Q4 2021.
- Funds reported $32.9M of Trevi Therapeutics stock for Q1 2022, up 220% quarter-over-quarter.
- 9 funds opened new Trevi Therapeutics positions in Q1 2022 and 3 closed out, a net change of +6 holders.
- The largest Trevi Therapeutics buyer in Q1 2022 was MAI Capital Management, an estimated $1.6M added.
- The largest Trevi Therapeutics seller in Q1 2022 was NEA Management Company, an estimated $6.15M sold.
Based on aggregated 13F filings for Q1 2022.